Literature DB >> 6454269

Peritoneoscopy--use in assessment of intra-abdominal malignancy.

G A Coupland, D M Townend, C J Martin.   

Abstract

Peritoneoscopy was performed on 236 patients between 1971 and 1980 to assess intraabdominal malignancy or to determine its presence when doubt existed. The diagnostic rate was 86%. The main causes of failure to reach a diagnosis were adhesions arising from previous surgery and tumor adhesions. It was a useful means of obtaining a tissue diagnosis, and the complication rate was low--4.5%. Peritoneoscopy demonstrated the cause of hepatomegaly in 90.9% of patients, the pathology of abdominal masses in 82.5%, and of ascites in 80.5%. It was also useful in assessing abdominal ultrasound and isotope liver scan abnormalities. The procedure is safe, cheap, and allows adequate assessment of intra-abdominal malignancy in a high proportion of patients.

Entities:  

Mesh:

Year:  1981        PMID: 6454269

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  Guidelines for diagnostic laparoscopy.SAGES guidelines. Society of American Gastrointestinal Endoscopic Surgeons.

Authors: 
Journal:  Surg Endosc       Date:  1999-02       Impact factor: 4.584

2.  Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel.

Authors:  Kunihiro Tsuji; Yosuke Kito; Saori Miyajima; Miwa Yonezawa; Anna Kubo; Kahori Ushijima; Hisashi Doyama
Journal:  Clin J Gastroenterol       Date:  2020-10-18

3.  Guidelines for diagnostic laparoscopy. Society of American Gastrointestinal Endoscopic Surgeons (SAGES).

Authors: 
Journal:  Surg Endosc       Date:  1993 Jul-Aug       Impact factor: 4.584

4.  Role of ascites adenosine deaminase in differentiating between tuberculous peritonitis and peritoneal carcinomatosis.

Authors:  Seung Joo Kang; Ji Won Kim; Jee Hyun Baek; Se Hyung Kim; Byeong Gwan Kim; Kook Lae Lee; Ji Bong Jeong; Yong Jin Jung; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.